TY - JOUR
T1 - Molecular screening for breast cancer prevention, early detection, and treatment planning
T2 - Combining biomarkers from DNA, RNA, and protein
AU - Stemke-Hale, Katherine
AU - Hennessy, Bryan
AU - Mills, Gordon B.
AU - Mitra, Rahul
PY - 2006/11
Y1 - 2006/11
N2 - The completion of the human genome project, along with the ancillary technologies derived from this effort, provides the ability to comprehensively analyze patient tumors as well as the individual patient's own genetic make-up at the DNA, RNA, and protein level. As a result, novel molecular screening techniques have the potential to push the boundaries of detection to even smaller tumors and also to allow accurate risk assessment, cancer prevention, and treatment planning in individual women. This review focuses on advances over the past 2 years in the use of molecular signatures and circulating tumor cells for early breast cancer detection and for prediction of response to therapy.
AB - The completion of the human genome project, along with the ancillary technologies derived from this effort, provides the ability to comprehensively analyze patient tumors as well as the individual patient's own genetic make-up at the DNA, RNA, and protein level. As a result, novel molecular screening techniques have the potential to push the boundaries of detection to even smaller tumors and also to allow accurate risk assessment, cancer prevention, and treatment planning in individual women. This review focuses on advances over the past 2 years in the use of molecular signatures and circulating tumor cells for early breast cancer detection and for prediction of response to therapy.
UR - http://www.scopus.com/inward/record.url?scp=33750717187&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33750717187&partnerID=8YFLogxK
U2 - 10.1007/s11912-006-0078-5
DO - 10.1007/s11912-006-0078-5
M3 - Review article
C2 - 17040626
AN - SCOPUS:33750717187
SN - 1523-3790
VL - 8
SP - 484
EP - 491
JO - Current oncology reports
JF - Current oncology reports
IS - 6
ER -